Abstract 2045P
Background
The success of cancer therapy relies on patient adherence, which refers to the extent to which a person's behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider ( WHO 2003 ). Several PROMs were developed to measure patient adherence to (cancer) therapy. In light of this, our study aims to offer a comprehensive overview of PROMs in the cancer field, with a specific focus on the adherence dimensions captured.
Methods
A systematic review of systematic reviews was performed to identify studies of cancer patients that apply PROMs to measure adherence without restriction to the type of therapy. Databases of Pubmed and Embase were searched up to March 2022 and studies were selected based on predefined eligibility criteria. A qualitative synthesis was used determining measurement of adherence and dimensions of PROMs according to the WHO definition for adherence.
Results
After screening 4483 results a total of 56 literature reviews were included capturing 1064 studies that focused on cancer patients. Out of the 56 literature reviews included in our final analysis, the majority (45) focused on medication adherence, while 18 studies assessed adherence to dietary recommendations, and 13 studies examined adherence to lifestyle changes. Three studies investigated other dimensions of adherence. Data collection was primarily carried out via questionnaires and most studies applied self-developed, non-validated PROMs. PROMs mainly measured one dimension of adherence, even though the content of items were overlapping between medication, diet and lifestyle.
Conclusions
This systematic literature review provides a comprehensive overview of PROMs used to assess adherence in oncology. Our analysis highlights the predominance of studies measuring medication adherence and underscores the need for greater attention to other dimensions of adherence. Our findings can inform the choice of PROMs to monitor patients’ adherence in clinical practice and enhance health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06